Skip to content
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH
Home
Blog
Biosimilars Council Press Releases
Blog
Blog
June 8, 2018
AAM
The 180-Day Rule Supports Generic Competition. Here’s How.
Blog
June 8, 2018
AAM
Seeking Asylum for Its Patents on Tribal Lands: The Latest Brand-Name Drug Company Strategy to Preserve Monopoly Pricing
Blog
June 8, 2018
AAM
#EndtheShenanigans, Says Gottlieb
Blog
June 8, 2018
AAM
How the Medicaid Generics Penalty Jeopardizes Patient Access
Blog
June 8, 2018
AAM
The Medicaid Generics Penalty: A Primer (Part 1)
Blog
June 8, 2018
AAM
The Generic Drug Supply Chain
Blog
June 8, 2018
AAM
Health Care Orgs Urge Congress to Take Close Look at Allergan Deal
Blog
June 8, 2018
AAM
Support the CREATES Act and Help Patients Win
Blog
June 8, 2018
AAM
Take Action on SB 17 to Protect Patient Access and Savings for Californians
Blog
June 8, 2018
AAM
NYT: Generic Drug Prices Are Falling, but Are Consumers Benefiting?
Blog
June 8, 2018
AAM
Learn to manage the GDUFA landscape at our CMC Workshop
Blog
June 8, 2018
AAM
Veto Maryland House Bill 631, Which Would Harm Patients by Chilling Generic Drug Competition
Load More
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Advocacy & Policy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2026
GRx+Biosims 2026
Press Releases
JOIN
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH
